SCHEMBL266871

SCHEMBL266871

O=C(Nc1ccc(Cl)cc1C(=O)NN=Cc1ccc(Cl)c(C(F)(F)F)c1)c1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.52
MEN1 O00255 7/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
KLF5 Q13887 1/20 0.49
POLB P06746 2/20 0.47
PSMD14 O00487 2/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
KCNMA1 Q12791 1/20 0.47
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SLC34A2 O95436 1/20 0.45
SLC34A1 Q06495 1/20 0.45
SLC34A3 Q8N130 1/20 0.45
SLC20A1 Q8WUM9 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274056 1.00 KMT2A (0.52) KMT2AMEN1NPC1RAB9AKLF5
SCHEMBL266870 1.00 KMT2A (0.52) KMT2AMEN1NPC1RAB9AKLF5
SCHEMBL267208 0.92 KMT2A (0.50) KMT2AMEN1NPC1RAB9AKLF5
SCHEMBL267209 0.92 KMT2A (0.50) KMT2AMEN1NPC1RAB9AKLF5
SCHEMBL273362 0.92 KMT2A (0.50) KMT2AMEN1NPC1RAB9AKLF5
SCHEMBL265300 0.89 RAB9A (0.49) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL265299 0.89 RAB9A (0.49) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL273521 0.89 RAB9A (0.49) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL273519 0.86 GRM4 (0.54) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL267332 0.86 GRM4 (0.54) KMT2AMEN1NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.